Nothing Special   »   [go: up one dir, main page]

BR112021002090A8 - Derivado azabicíclico opticamente ativo - Google Patents

Derivado azabicíclico opticamente ativo

Info

Publication number
BR112021002090A8
BR112021002090A8 BR112021002090A BR112021002090A BR112021002090A8 BR 112021002090 A8 BR112021002090 A8 BR 112021002090A8 BR 112021002090 A BR112021002090 A BR 112021002090A BR 112021002090 A BR112021002090 A BR 112021002090A BR 112021002090 A8 BR112021002090 A8 BR 112021002090A8
Authority
BR
Brazil
Prior art keywords
optically active
azabicyclic derivative
derivative
active azabicyclic
mll
Prior art date
Application number
BR112021002090A
Other languages
English (en)
Other versions
BR112021002090A2 (pt
Inventor
Kamioka Seiji
Ban Hitoshi
Shimada Naoaki
Hirose Wataru
Arakawa Akihiko
Yamazaki Kazuto
Hira Kenjiro
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of BR112021002090A2 publication Critical patent/BR112021002090A2/pt
Publication of BR112021002090A8 publication Critical patent/BR112021002090A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"DERIVADO AZABICÍCLICO OPTICAMENTE ATIVO". A presente invenção refere-se ao composto de fórmula (1a) em que p é 1 ou 2, R1 - R4 são átomo de hidrogênio ou similar, e a - d são 1 ou 2, ou um sal farmaceuticamente aceitável do mesmo, o qual tem um efeito antitumoral através da inibição da ligação entre uma proteína de fusão de MLL que é infundida com AF4, AF9, ou similar, que é um gene parceiro de fusão representativo causando leucemia MLL, e menin.
BR112021002090A 2018-08-27 2019-08-26 Derivado azabicíclico opticamente ativo BR112021002090A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-158315 2018-08-27
JP2018158315 2018-08-27
PCT/JP2019/033234 WO2020045334A1 (ja) 2018-08-27 2019-08-26 光学活性なアザビシクロ環誘導体

Publications (2)

Publication Number Publication Date
BR112021002090A2 BR112021002090A2 (pt) 2021-05-04
BR112021002090A8 true BR112021002090A8 (pt) 2022-12-06

Family

ID=69644540

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021002090A BR112021002090A8 (pt) 2018-08-27 2019-08-26 Derivado azabicíclico opticamente ativo

Country Status (14)

Country Link
US (3) US11369605B2 (pt)
EP (1) EP3845533A4 (pt)
JP (3) JP6671574B1 (pt)
KR (1) KR20210049136A (pt)
CN (1) CN112585140B (pt)
AU (1) AU2019327006B2 (pt)
BR (1) BR112021002090A8 (pt)
CA (1) CA3107743A1 (pt)
EA (1) EA202190623A1 (pt)
MX (1) MX2021002424A (pt)
PH (1) PH12021550229A1 (pt)
SG (1) SG11202101085PA (pt)
TW (1) TWI815954B (pt)
WO (1) WO2020045334A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020032105A1 (ja) * 2018-08-08 2020-02-13 大日本住友製薬株式会社 光学活性な架橋型ピペリジン誘導体
EP3845533A4 (en) * 2018-08-27 2022-04-27 Sumitomo Dainippon Pharma Co., Ltd. OPTICALLY ACTIVE AZABICYCLIC DERIVATIVES
JPWO2021060453A1 (pt) * 2019-09-27 2021-04-01
JP7454520B2 (ja) 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
WO2022130270A1 (en) 2020-12-17 2022-06-23 Astrazeneca Ab N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
JP2024518425A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
KR20240006542A (ko) 2021-05-08 2024-01-15 얀센 파마슈티카 엔브이 치환된 스피로 유도체
CA3239857A1 (en) * 2021-12-03 2023-06-08 Bionova Pharmaceuticals (Shanghai) Limited Carbonyl substituted diazaspiro compounds and its use
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
AR039208A1 (es) 2002-04-03 2005-02-09 Syngenta Participations Ag Compuestos de fenil- y piridilalquinos, composicion herbicida que los contiene, procedimiento de preparacion de aquellos y procedimiento para combatir el crecimiento de plantas indeseadas
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CL2008000197A1 (es) 2007-01-26 2008-08-01 Smithkline Beecham Corp Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
US9878987B2 (en) 2014-05-13 2018-01-30 Memorial Sloan Kettering Cancer Center HSP70 modulators and methods for making and using the same
CA3005945A1 (en) * 2015-12-22 2017-06-29 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
PL3468966T3 (pl) * 2016-06-10 2021-04-06 Vitae Pharmaceuticals, Llc Inhibitory interakcji menina-mll
MA46228A (fr) * 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
IL295972A (en) 2016-09-16 2022-10-01 Vitae Pharmaceuticals Llc Inhibitors of the menin-mil interaction
EA201990699A1 (ru) 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
EP3562823B1 (en) * 2016-12-28 2023-02-08 Promega Corporation Functionalized nanoluc inhibitors
JP7239562B2 (ja) 2018-03-30 2023-03-14 住友ファーマ株式会社 光学活性な架橋型環状２級アミン誘導体
EP3845533A4 (en) * 2018-08-27 2022-04-27 Sumitomo Dainippon Pharma Co., Ltd. OPTICALLY ACTIVE AZABICYCLIC DERIVATIVES
US10815241B2 (en) * 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative

Also Published As

Publication number Publication date
CN112585140B (zh) 2023-07-04
SG11202101085PA (en) 2021-03-30
US11911381B2 (en) 2024-02-27
CN112585140A (zh) 2021-03-30
AU2019327006A1 (en) 2021-03-04
US20240148727A1 (en) 2024-05-09
US20210338668A1 (en) 2021-11-04
US11369605B2 (en) 2022-06-28
JP2023134729A (ja) 2023-09-27
TWI815954B (zh) 2023-09-21
PH12021550229A1 (en) 2021-10-11
JP6671574B1 (ja) 2020-03-25
KR20210049136A (ko) 2021-05-04
US20220288072A1 (en) 2022-09-15
TW202024082A (zh) 2020-07-01
EP3845533A4 (en) 2022-04-27
AU2019327006B2 (en) 2024-02-15
EA202190623A1 (ru) 2021-05-21
WO2020045334A1 (ja) 2020-03-05
EP3845533A1 (en) 2021-07-07
JPWO2020045334A1 (ja) 2020-09-03
CA3107743A1 (en) 2020-03-05
JP2020105191A (ja) 2020-07-09
BR112021002090A2 (pt) 2021-05-04
JP7317749B2 (ja) 2023-07-31
MX2021002424A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
BR112021002090A8 (pt) Derivado azabicíclico opticamente ativo
MX2020013853A (es) Compuestos innovadores.
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
CO4940462A1 (es) 4,5-diarilimidazoles 2-sustituidos
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
WO2019084118A3 (en) Compositions of phosphorylated tau peptides and uses thereof
BR112021018238A2 (pt) Derivados de azolopiridina macrocíclicos como moduladores de eed e prc2
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
MX2019002864A (es) Mezcla aditiva.
MX2023014281A (es) Lipidos novedosos.
MD20230027A2 (ro) Amestecuri de pesticide cu conţinut de indazoli
NZ746906A (en) Oxaborole esters and uses thereof
MX2021003427A (es) Nuevos oxadiazoles.
MX2021014680A (es) Derivado de benzotriazol.
PH12019502868A1 (en) Composition for injection
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
WO2018039077A8 (en) Therapeutic compounds
ZA202006439B (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators
MY197244A (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MY195906A (en) Novel Bisphosphonic Acid Compound

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)